Greater decrease of fibrinogen as compared to antithrombin III in L-asparaginase treated leukemia patients.

Area of Science:

• Hematology
• Pediatric Oncology
• Clinical Biochemistry

Background:

• Acute lymphoblastic leukemia (ALL) is a common childhood cancer.
• Remission induction therapy for ALL often involves complex chemotherapy regimens.
• Understanding treatment-related hemostatic changes is crucial for managing pediatric ALL patients.

Purpose of the Study:

• To investigate sequential changes in fibrinogen and Antithrombin III (AT III) levels during remission induction therapy for acute lymphoblastic leukemia (ALL) in children.
• To assess the impact of L-asparaginase, prednisone, and vincristine on key hemostatic factors.
• To determine if these changes are reversible after treatment cessation.

Main Methods:

• Sequential monitoring of plasma fibrinogen and Antithrombin III (AT III) levels (antigen and activity).
• Study conducted on 20 pediatric patients with acute lymphoblastic leukemia (ALL) undergoing remission induction therapy.
• Statistical analysis to determine significance of changes from baseline values.

Main Results:

• Significant decreases in plasma fibrinogen concentrations were observed within the first two weeks of therapy (p < 0.05 or p < 0.01).
• Antithrombin III (AT III) levels (antigen and activity) decreased between weeks one and two, remaining near lower normal limits (p < 0.05).
• All measured hemostatic parameters gradually returned to normal levels following the completion of L-asparaginase treatment.

Conclusions:

• L-asparaginase-based chemotherapy for pediatric ALL induces temporary reductions in fibrinogen and Antithrombin III (AT III).
• These hemostatic factor levels demonstrate reversibility, normalizing after the cessation of L-asparaginase therapy.
• Monitoring hemostatic parameters may be important during ALL treatment to manage potential complications.